Inage

Docket Number: 037003-0275537

PATENT APPLICATION

Client Reference: 1998-30-0524A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

)

In e the Application of

GRILLO-LOPEZ et al.

Group Art Unit: 1644

Application No.: 09/436,348

Examiner: Ronald B. Schwadron

Filed: November 9, 1999

Confirmation No.: 6492

For: USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING

AGENT IN PATIENTS BMT OR PBSC TRANSPLANT

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits in the present application. No certification or fee is required.

Respectfully submitted,

I La Cauly 1

Thomas A. Cawley, Jr., Ph.D. Registration Number 40,944

Date: December 24, 2003 PILLSBURY WINTHROP LLP Telephone: (703) 905-2000 Facsimile: (703) 905-2500

P.O. Box 10500 McLean, VA 22102

TAC/JBM:ntb

To: U.S (PW FO	PTO-1449 (mo Department RM PAT-144 and Trademar	of Commerce	, 5003	OFFICE				Atty. Dkt. No.	M#		Client Re	f.	,	
Jan Tal									0275537		1998-30-0524A			
INFORMATION DISCLOSURE SPÄTEMENT BY APPLICANT								Applicant: GRILLO-LOPEZ et al.						
								Appln. No.: 09/436,348						
					_		_	Filing Dat	e: November	9, 1999				
Date: [December 2	4, 2003	Page	1	of	1	<u> </u>	Examine	: R. Schwadr	on Gro	up Art Ur	it:	1644	
U.S. PA	TENT DOC	UMENTS												
Examiner's Initials*		Document Number		Date MM/YYYY		Name (Family Name		of First Inventor)		Class	Sub Class		Filing Date	
	AR													
	BR	ļ		<u> </u>									ļ	
	CR												ļ	
	DR			 						_			<u> </u>	
	ER			 			• • •			 			 	
FOREI	FR			<u> </u>		<u> </u>				 			<u> </u>	
FOREIG	SN PATENT	DOCUMENT Document Number	Country			Inventor	Name	·. ·		English Abstract		Translation Readily Available		
	GR													T
	HR													
	IR													
	JR		<u> </u>									\perp	ļ	\perp
	KR		ļ		ļ								ļ	\bot
	LR							···· ·						
OTHER	I	T				_								
	MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.												
	NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.												
	OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting</i> , p. 852, Abstract No. 622.												
	PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.												
	QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.												
	RR								herapy With Io Oncology, Vol.					
	SR								nronic lymphod B8, rituximab),					
Examiner						Date Considered:								
*EXAM		ial if citation cor not considered.							e with MPEP §	509. Draw	line throu	ıgh (citation if	not

30398286v1